ReviewCurrent diabetes reports2025
Preventive and therapeutic strategies via health care delivery system to minimize sight-threatening diabetic retinopathy: a narrative review.
Review in Current diabetes reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Noncoding RNAs as novel diagnostic biomarkers for diabetic retinopathy: A systematic review and meta-analysis.Journal of diabetes investigation · 2026Article
- Intelligent Staging Performance of Diabetic Retinopathy Based on Fundus Fluorescein Angiography Images with Different Angiographic Phases.Bioengineering (Basel, Switzerland) · 2026Article
- Low serum dehydroepiandrosterone sulfate is related to diabetic retinopathy in males with type 2 diabetes mellitus.Journal of translational medicine · 2026Article
- Exploring Patient Involvement in Treatment Decision-Making for Diabetic Retinopathy: A COM-B Model-Based Cross-Sectional Survey.Patient preference and adherence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo highlight various preventive and therapeutic strategies via health care delivery system to minimize sight-threatening diabetic retinopathy. RECENT
findingsDiabetic retinopathy (DR) is a common and specific microvascular complication of diabetes and is a common cause of blindness among economic age groups or the working population of the country. Clinically, DR can be graded as non-sight-threatening diabetic retinopathy (NSTDR), including mild and moderate non-proliferative abnormalities and sight-threatening diabetic retinopathy (STDR), which comprises of severe non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), or clinically significant macular edema (CSME). In STDR, the disease progresses to the proliferative phase which is characterized by the formation of new blood vessels and macular edema owing to the accumulation of fluid within the retina, producing severe and often irreversible vision loss. With the influx of artificial intelligence in the medical arena, there is a continuous rise in the demand for the development of automated analysis software for the analysis of retinal images in people with diabetes. Nowadays, Smartphone-based retinal imaging has emerged as one of the most cost-effective ways of screening for DR in the community, which even non-ophthalmologists can do. Understanding the factors associated with STDR can help to develop primary and secondary prevention strategies. Spreading awareness regarding STDR at the community level is crucial. All diabetic patients need regular and repetitive follow-ups with the ophthalmologist for screening and timely treatment of DR, particularly STDR. Preservation of sight in STDR can be achieved through effective screening, timely laser treatment, intraocular injection of steroids and anti-vascular endothelial growth-factor agents and intraocular surgery.
Indexed as
Identifiers
40493103What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.